March 20, 2020 / 9:59 PM / 19 days ago

BRIEF-Imstem Biotech Says FDA Lifted Clinical Hold On Testing Treatment For Multiple Sclerosis

March 20 (Reuters) - ImStem Biotechnology Inc:

* IMSTEM BIOTECHNOLOGY ANNOUNCES FDA HAS LIFTED THE CLINICAL HOLD ON THE INVESTIGATIONAL NEW DRUG APPLICATION FOR IMS001 FOR THE TREATMENT OF MULTIPLE SCLEROSIS

* IMSTEM - PLANS TO INITIATE PHASE 1 CLINICAL STUDY IN PATIENTS WITH RELAPSING-REMITTING, SECONDARY & PRIMARY PROGRESSIVE FORMS OF MS IN 2020 IN US Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below